Movicol (Sodium Hydrogen Carbonate, Potassium Chloride, Sodium Chloride, Macrogol 3350)

Macrogol 3350 is a large polyethylene glycol molecule that remains in the gut and draws water into the intestinal lumen by osmosis. The added electrolytes help maintain fluid balance, resulting in softer stools that stimulate normal peristalsis and promote evacuation.

The dose of Movicol is individualized by the prescribing healthcare professional based on the patient’s age, severity of constipation, and clinical response. The prescriber determines the appropriate volume of the oral solution and any necessary adjustments.

Safety data for Movicol during pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Movicol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with stimulant laxatives, Movicol works by osmotic water retention rather than stimulating intestinal muscle activity, resulting in a gentler, more physiologic effect. It is often preferred for long‑term management because it has a lower risk of dependence and fewer cramping side effects.

Store Movicol at ambient temperature, preferably below 25 °C. Keep the bottle tightly closed in its original packaging, protect it from moisture and direct sunlight, and discard any solution that appears discoloured or contaminated.

Movicol is taken orally as a measured volume of the clear solution. It should be mixed with water or a suitable beverage as directed by the prescriber, and consumed with or without food according to individual tolerance.

Serious risks include severe dehydration, significant electrolyte imbalances such as hyponatraemia or hyperkalaemia, and rare allergic reactions that may present as rash, swelling or breathing difficulty. Patients should seek immediate medical attention if any of these symptoms develop.

Movicol should be avoided in individuals with known hypersensitivity to any of its components, in patients with intestinal obstruction or perforation, and in those with severe renal impairment unless closely monitored. A healthcare professional should evaluate suitability before initiating therapy.